Alzheimer Disease in Down Syndrome
نویسندگان
چکیده
منابع مشابه
Treatment of Alzheimer disease in Down syndrome
Down syndrome (DS) is the most common genetically driven intellectual disability. Neuro pathological evidence of an associa‐ tion between Alzheimer disease (AD) and DS was published 11 years before trisomy 21 was described as the cause of DS.1 AD‐type pathology is almost universal in patients with DS in their 40s, although the develop ment of clinically detectable cognitive decline typically la...
متن کاملCerebrovascular pathology in Down syndrome and Alzheimer disease
People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD) with age. Typically, by age 40 years, most people with DS have sufficient neuropathology for an AD diagnosis. Interestingly, atherosclerosis and hypertension are atypical in DS with age, suggesting the lack of these vascular risk factors may be associated with reduced cerebrovascular pathology. However, becaus...
متن کاملDissecting Alzheimer disease in Down syndrome using mouse models
Down syndrome (DS) is a common genetic condition caused by the presence of three copies of chromosome 21 (trisomy 21). This greatly increases the risk of Alzheimer disease (AD), but although virtually all people with DS have AD neuropathology by 40 years of age, not all develop dementia. To dissect the genetic contribution of trisomy 21 to DS phenotypes including those relevant to AD, a range o...
متن کاملAmyloid plaque core protein in Alzheimer disease and Down syndrome.
We have purified and characterized the cerebral amyloid protein that forms the plaque core in Alzheimer disease and in aged individuals with Down syndrome. The protein consists of multimeric aggregates of a polypeptide of about 40 residues (4 kDa). The amino acid composition, molecular mass, and NH2-terminal sequence of this amyloid protein are almost identical to those described for the amyloi...
متن کاملDown syndrome and Alzheimer disease: response to donepezil.
BACKGROUND Individuals with Down syndrome who develop Alzheimer disease may show an improvement in cognitive functioning after treatment with acetylcholinesterase inhibitors. OBJECTIVE To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment. DESIGN A nonrandomized controlled trial using donepezil in a pilot stu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Neurology Briefs
سال: 1989
ISSN: 2166-6482,1043-3155
DOI: 10.15844/pedneurbriefs-3-8-3